Our Newsroom

At Accord BioPharma, we’re never content with the status quo.

Accord BioPharma on LinkedIn

What happens early in rheumatoid arthritis can influence what comes next. Achieving remission or low disease activity isn't just about symptom con...

Read more

This September, we came together with a shared purpose— to make a difference. Our team recently participated in a blood donation drive, coming t...

Read more

Treating advanced prostate cancer requires partnership – between patients and providers, between innovation and practicality. Providers need solutio...

Read more

Prostate cancer can vary from person to person, from disease progression and recurrence to treatment response and quality of life. But how much do we...

Read more

Bone metastases can affect more than the skeleton—they can impact mobility, treatment continuity, and quality of life. Recognizing the importance...

Read more

Biosimilars are developed through a foundation of rigorous science and regulatory oversight.  And understanding how they're developed is key to app...

Read more

We’ve built an exceptional foundation within the Accord Family, and that’s how we’re able to go Beyond Biology. Today,...

Read more

The biosimilar landscape is evolving and transforming patient access to healthcare.   In the United States, the biosimilars market is experiencing ...

Read more

The biosimilar market has transformed the number of patients who have access to life-changing treatments, but there’s more work to do.     At Acc...

Read more

Read more

Chronic disease doesn’t clock out at 5 PM. For the nearly 6 in 10 people in the U.S. living with a chronic disease, life looks different in ways mos...

Read more

Here’s what makes a biosimilar a biosimilar: its manufacturing source.

Read more

Biosimilars are no longer a niche product; they're reshaping how patients access treatment.    Over the past decade, the biosimilar market has matur...

Read more

Not every ache is "just aging."  Persistent joint pain, stiffness, swelling, and fatigue could be early signs of rheumatoid arthritis. Recognizing...

Read more

Meet Accord: Our first biosimilar in immunology has National Preferred Formulary placement through one of the nation's largest PBMs. We're offering a ...

Read more

Connect With Us